65,437 trials
Sars-CoV2 · COVID
Primary: Composite Outcome of Arterial Thromboembolic Events, Venous Thromboembolic Events and All-cause Mortality at Day 30 ± 2 Days. — 25; 31 Participants
Acquired Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Related Events — 37.9; 8.2 percentage of participants
Safety · Acceptability
Primary: Number of Participants That Successfully Insert Vaginal Film — 8; 8; 22; 22 Participants — p=>.99
Aphakia · Cataract
Primary: Magnitude of Manifest Cylinder (MRCYL) Compared Between the Two Study Groups, LAL and Control — -0.319; -0.452 Diopter
B-cell Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Overall Remission Rate (ORR) as Determined by Independent Review Committee (IRC) Assessment. — 82.3; 100.0 Percentage of participants…
COVID-19
Primary: Time to Recovery for Participants With Baseline Ordinal Score 4, 5 and 6 — 5.0; 5.0 Days — p=0.880
Dry Eye Disease (DED)
Primary: Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28) — 123; 121; 70 Participants
Long Term Follow up Dry Eye Disease
Primary: Number of Participants With the Left Nostril/Abnormal at 6 Months as Assessed by Intranasal Examinations — 0; 0; 0; 0 Participants
Cancer · Palliative Radiotherapy
Primary: Percentage of Patients With Treatment-related, Non-hematologic, Grade 3 or Higher Adverse Events — 1 Participants
Central Neuropathic Pain · Multiple Sclerosis
Primary: Association Between the Dextromethorphan Plasma Concentration and the Change From Baseline Pain Rating Scale (PRS) Score to the Average Pain Rating Scale Score During…
HIV · Acute HIV Infection
Primary: Number of Participants With Viral Load Measurement <200 Copies/mL at Week 24 — 34 Participants
Atopic Dermatitis
Primary: Percent Changes From Baseline in Pruritus Visual Analogue Scale (VAS) at Week 12 — -20.07; -41.46; -61.24; -60.46 percentage change — p=0.0027
Adult Lymphocyte Depletion Hodgkin Lymphoma · Adult Lymphocyte Predominant Hodgkin Lymphoma · Adult Mixed Cellularity Hodgkin Lymphoma
Primary: Adverse Events in Terms of Dose-limiting Toxicity (DLT) and MTD of Bendamustine Hydrochloride (Phase I) — 0; 0; 0; 0 number of patients
Attention Deficit Hyperactivity Disorder Symptoms
Primary: System Usability Scale — 71 score on a scale
Smoking Cessation
Primary: Efficacy - 4 Weeks of Continuous Abstinence From Smoking Cigarettes — 14; 14; 32; 36 Participants